Terms ending in 2027
Every in-force patent on Abraxis Bioscience, LLC's record whose computed term ends in 2027, whoever holds it now. Soonest term end first, then patent number.
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 8,026,275 | Compositions, Methods of Use and Preparation of 2,6-Diisopropyl Phenol and Analogs for Ischemic Injury In force · High confidence | Nantbioscience, Inc. | In force | High confidence | |
| US 8,735,394 | Combinations and Modes of Administration of Therapeutic Agents and Combination Therapy In force · High confidence | Abraxis Bioscience, LLC | In force | High confidence | |
| US 7,858,782 | Triazine Derivatives and Their Therapeutical Applications In force · High confidence | Nantbioscience, Inc. | In force | High confidence | |
| US 8,999,396 | Breast Cancer Therapy Based on Hormone Receptor Status with Nanoparticles Comprising Taxane In force · High confidence | Abraxis Bioscience, LLC | In force | High confidence | |
| US 9,675,578 | Breast Cancer Therapy Based on Hormone Receptor Status with Nanoparticles Comprising Taxane In force · High confidence | Abraxis Bioscience, LLC | In force | High confidence | |
| US 9,724,323 | Breast Cancer Therapy Based on Hormone Receptor Status with Nanoparticles Comprising Taxane In force · High confidence | Abraxis Bioscience, LLC | In force | High confidence | |
| US 10,682,420 | Breast Cancer Therapy Based on Hormone Receptor Status with Nanoparticles Comprising Taxane In force · High confidence | Abraxis Bioscience, LLC | In force | High confidence |
7 of 7 patents shown. Soonest term end first, then patent number.
5 of these are in force and held by Abraxis Bioscience, LLC.
Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.